Table of Contents Author Guidelines Submit a Manuscript
Parkinson’s Disease
Volume 2015, Article ID 131508, 7 pages
http://dx.doi.org/10.1155/2015/131508
Clinical Study

Transdermal Rotigotine Improves Sleep Fragmentation in Parkinson’s Disease: Results of the Multicenter, Prospective SLEEP-FRAM Study

1Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain
2Hospital Santa Maria de Lleida, 25007 Lleida, Spain
3Hospital de Mataró, 08302 Barcelona, Spain
4Hospital del Mar, 08003 Barcelona, Spain
5Hospital de Granollers, 08401 Barcelona, Spain
6Hospital Son Espases, 07120 Barcelona, Spain
7Corporació Sanitària Parc Taulí, 08208 Barcelona, Spain
8Hospital de Martorell, 08760 Martorell, Spain
9Hospital General de Catalunya, 08915 Barcelona, Spain
10Hospital de Figueres, 17600 Girona, Spain
11Hospital Germans Trias i Pujol, 07014 Barcelona, Spain

Received 17 November 2014; Revised 3 February 2015; Accepted 5 February 2015

Academic Editor: Antonio Pisani

Copyright © 2015 Javier Pagonabarraga et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. Tandberg, J. P. Larsen, and K. Karlsen, “A community-based study of sleep disorders in patients with Parkinson's disease,” Movement Disorders, vol. 13, no. 6, pp. 895–899, 1998. View at Publisher · View at Google Scholar · View at Scopus
  2. C. L. Comella, “Sleep disorders in Parkinson's disease: an overview,” Movement Disorders, vol. 22, supplement S17, pp. S367–S373, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. P. Barone, A. Antonini, C. Colosimo et al., “The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease,” Movement Disorders, vol. 24, no. 11, pp. 1641–1649, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. M. D. Gjerstad, T. Wentzel-Larsen, D. Aarsland, and J. P. Larsen, “Insomnia in Parkinson's disease: frequency and progression over time,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 78, no. 5, pp. 476–479, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. D. G. Gunn, S. L. Naismith, and S. J. G. Lewis, “Sleep disturbances in parkinson disease and their potential role in heterogeneity,” Journal of Geriatric Psychiatry and Neurology, vol. 23, no. 2, pp. 131–137, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. G. W. Duncan, T. K. Khoo, A. J. Yarnall et al., “Health-related quality of life in early Parkinson's disease: the impact of nonmotor symptoms,” Movement Disorders, vol. 29, no. 2, pp. 195–202, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. J. C. Gómez-Esteban, B. Tijero, J. Somme et al., “Impact of psychiatric symptoms and sleep disorders on the quality of life of patients with Parkinson's disease,” Journal of Neurology, vol. 258, no. 3, pp. 494–499, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Caap-Ahlgren and O. Dehlin, “Insomnia and depressive symptoms in patients with Parkinson's disease: relationship to health-related quality of life. An interview study of patients living at home,” Archives of Gerontology and Geriatrics, vol. 32, no. 1, pp. 23–33, 2001. View at Publisher · View at Google Scholar · View at Scopus
  9. K. H. Karlsen, J. P. Larsen, E. Tandberg, and J. G. Mæland, “Influence of clinical and demographic variables on quality of life in patients with Parkinson's disease,” Journal of Neurology Neurosurgery and Psychiatry, vol. 66, no. 4, pp. 431–435, 1999. View at Publisher · View at Google Scholar · View at Scopus
  10. S. L. Naismith, I. B. Hickie, and S. J. G. Lewis, “The role of mild depression in sleep disturbance and quality of life in Parkinson's disease,” The Journal of Neuropsychiatry and Clinical Neurosciences, vol. 22, no. 4, pp. 384–389, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. A. B. Neikrug, J. E. Maglione, L. Liu et al., “Effects of sleep disorders on the non-motor symptoms of Parkinson disease,” Journal of Clinical Sleep Medicine, vol. 9, no. 11, pp. 1119–1129, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. P. Viwattanakulvanid, L. Kaewwilai, O. Jitkritsadakul et al., “The impact of the nocturnal disabilities of Parkinson's disease on caregivers' burden: implications for interventions,” Journal of Neural Transmission, vol. 121, no. 1, supplement, pp. 15–24, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. B. Porter, R. MacFarlane, and R. Walker, “The frequency and nature of sleep disorders in a community-based population of patients with Parkinson's disease,” European Journal of Neurology, vol. 15, no. 1, pp. 50–54, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. M. I. Norlinah, K. N. Afidah, A. T. Noradina et al., “Sleep disturbances in Malaysian patients with Parkinson's disease using polysomnography and PDSS,” Parkinsonism and Related Disorders, vol. 15, no. 9, pp. 670–674, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. L. Priano, G. Albani, A. Brioschi et al., “Nocturnal anomalous movement reduction and sleep microstructure analysis in parkinsonian patients during 1-night transdermal apomorphine treatment,” Neurological Sciences, vol. 24, no. 3, pp. 207–208, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. I. Reuter, C. M. Ellis, and K. Ray Chaudhuri, “Nocturnal subcutaneous apomorphine infusion in Parkinson's disease and restless legs syndrome,” Acta Neurologica Scandinavica, vol. 100, no. 3, pp. 163–167, 1999. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Zibetti, M. Rizzone, A. Merola et al., “Sleep improvement with levodopa/carbidopa intestinal gel infusion in Parkinson disease,” Acta Neurologica Scandinavica, vol. 127, no. 5, pp. e28–e32, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. K. R. Chaudhuri and K. Logishetty, “Dopamine receptor agonists and sleep disturbances in Parkinson's disease,” Parkinsonism & Related Disorders, vol. 15, supplement 4, pp. S101–S104, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. C. Trenkwalder, B. Kies, M. Rudzinska et al., “Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER),” Movement Disorders, vol. 26, no. 1, pp. 90–99, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. A. J. Hughes, S. E. Daniel, L. Kilford, and A. J. Lees, “Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases,” Journal of Neurology Neurosurgery and Psychiatry, vol. 55, no. 3, pp. 181–184, 1992. View at Publisher · View at Google Scholar · View at Scopus
  21. C. L. Tomlinson, R. Stowe, S. Patel, C. Rick, R. Gray, and C. E. Clarke, “Systematic review of levodopa dose equivalency reporting in Parkinson's disease,” Movement Disorders, vol. 25, no. 15, pp. 2649–2653, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. P. A. LeWitt, B. Boroojerdi, D. MacMahon, J. Patton, and J. Jankovic, “Overnight switch from oral dopaminergic agonists to transdermal rotigotine patch in subjects with Parkinson disease,” Clinical Neuropharmacology, vol. 30, no. 5, pp. 256–265, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. W. H. Poewe, O. Rascol, N. Quinn et al., “Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial,” The Lancet Neurology, vol. 6, no. 6, pp. 513–520, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. C. Trenkwalder, R. Kohnen, B. Högl et al., “Parkinson's disease sleep scale-validation of the revised version PDSS-2,” Movement Disorders, vol. 26, no. 4, pp. 644–652, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. G. T. Stebbins and C. G. Goetz, “Factor structure of the unified Parkinson's disease rating scale: motor examination section,” Movement Disorders, vol. 13, no. 4, pp. 633–636, 1998. View at Publisher · View at Google Scholar · View at Scopus
  26. F. S. Ertan, T. Ertan, G. Kiziltan, and H. Uyguçgil, “Reliability and validity of the geriatric depression scale in depression in Parkinson's disease,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 76, no. 10, pp. 1445–1447, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. J. Meara, E. Mitchelmore, and P. Hobson, “Use of the GDS-15 geriatric depression scale as a screening instrument for depressive symptomatology in patients with Parkinson's disease and their carers in the community,” Age and Ageing, vol. 28, no. 1, pp. 35–38, 1999. View at Publisher · View at Google Scholar · View at Scopus
  28. K. R. Chaudhuri, S. Pal, A. DiMarco et al., “The Parkinson's disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson's disease,” Journal of Neurology Neurosurgery and Psychiatry, vol. 73, no. 6, pp. 629–635, 2002. View at Publisher · View at Google Scholar · View at Scopus
  29. C. J. Fowler, D. Griffiths, and W. C. de Groat, “The neural control of micturition,” Nature Reviews Neuroscience, vol. 9, no. 6, pp. 453–466, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. A. Romigi, P. Stanzione, M. G. Marciani et al., “Effect of cabergoline added to levodopa treatment on sleep-wake cycle in idiopathic Parkinson's disease: an open label 24-hour polysomnographic study,” Journal of Neural Transmission, vol. 113, no. 12, pp. 1909–1913, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Cicolin, L. Lopiano, M. Zibetti et al., “Effects of deep brain stimulation of the subthalamic nucleus on sleep architecture in parkinsonian patients,” Sleep Medicine, vol. 5, no. 2, pp. 207–210, 2004. View at Publisher · View at Google Scholar · View at Scopus
  32. N. A. Reynolds, K. Wellington, and S. E. Easthope, “Rotigotine: in Parkinson's Disease,” CNS Drugs, vol. 19, no. 11, pp. 973–981, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. S. Clemens, D. Rye, and S. Hochman, “Restless legs syndrome: revisiting the dopamine hypothesis from the spinal cord perspective,” Neurology, vol. 67, no. 1, pp. 125–130, 2006. View at Publisher · View at Google Scholar · View at Scopus
  34. P. Han, S. T. Nakanishi, M. A. Tran, and P. J. Whelan, “Dopaminergic modulation of spinal neuronal excitability,” The Journal of Neuroscience, vol. 27, no. 48, pp. 13192–13204, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. R. Sakakibara, T. Uchiyama, T. Yamanishi, and M. Kishi, “Genitourinary dysfunction in Parkinson's disease,” Movement Disorders, vol. 25, no. 1, pp. 2–12, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. R. Sakakibara, F. Tateno, M. Kishi, Y. Tsuyuzaki, T. Uchiyama, and T. Yamamoto, “Pathophysiology of bladder dysfunction in Parkinson's disease,” Neurobiology of Disease, vol. 46, no. 3, pp. 565–571, 2012. View at Publisher · View at Google Scholar · View at Scopus
  37. D. Scheller, C. Ullmer, R. Berkels, M. Gwarek, and H. Lübbert, “The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson's disease,” Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 379, no. 1, pp. 73–86, 2009. View at Publisher · View at Google Scholar · View at Scopus